BR112023006710A2 - Métodos de fabricação de nanopartícula lipídica e composições derivadas da mesma - Google Patents
Métodos de fabricação de nanopartícula lipídica e composições derivadas da mesmaInfo
- Publication number
- BR112023006710A2 BR112023006710A2 BR112023006710A BR112023006710A BR112023006710A2 BR 112023006710 A2 BR112023006710 A2 BR 112023006710A2 BR 112023006710 A BR112023006710 A BR 112023006710A BR 112023006710 A BR112023006710 A BR 112023006710A BR 112023006710 A2 BR112023006710 A2 BR 112023006710A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- disclosed
- manufacturing methods
- nalnps
- lnp
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 5
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 6
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 101000979498 Homo sapiens Ninein-like protein Proteins 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000003058 natural language processing Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Optics & Photonics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
métodos de fabricação de nanopartícula lipídica e composições derivadas da mesma. são divulgados neste documento métodos para aumentar a potência de nanopartículas lipídicas carregadas com ácido nucleico (nalnps) por meio de certas técnicas de fabricação de lnp novas e surpreendentemente superiores. também são divulgadas composições farmacêuticas contendo nalnps fabricados de acordo com os métodos de fabricação descritos neste documento. os métodos divulgados neste documento superam grandes dificuldades técnicas e altos custos associados às técnicas de fabricação de lnp anteriores. os métodos divulgados neste documento, portanto, aprimoram muito a produção industrial de lnps de maneiras inesperadas proporcionando, assim, nalnps mais potentes para distribuição de ácido nucleico. especificamente, a invenção divulgada neste documento se refere a métodos que mostram nalnps de maior potência devido ao aumento da concentração de mistura dos lipídios e mrna durante a montagem.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063091603P | 2020-10-14 | 2020-10-14 | |
US202063091616P | 2020-10-14 | 2020-10-14 | |
US202163179872P | 2021-04-26 | 2021-04-26 | |
US202163179885P | 2021-04-26 | 2021-04-26 | |
PCT/US2021/054839 WO2022081752A1 (en) | 2020-10-14 | 2021-10-13 | Methods of lipid nanoparticle manufacture and compostions derived therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023006710A2 true BR112023006710A2 (pt) | 2023-10-03 |
Family
ID=81208588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023006710A BR112023006710A2 (pt) | 2020-10-14 | 2021-10-13 | Métodos de fabricação de nanopartícula lipídica e composições derivadas da mesma |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220235377A1 (pt) |
EP (2) | EP4229208A1 (pt) |
JP (2) | JP2023546175A (pt) |
KR (1) | KR20230118715A (pt) |
AU (2) | AU2021360494A1 (pt) |
BR (1) | BR112023006710A2 (pt) |
CA (2) | CA3195123A1 (pt) |
IL (1) | IL301890A (pt) |
MX (1) | MX2023004371A (pt) |
TW (2) | TW202229228A (pt) |
WO (2) | WO2022081750A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116813493A (zh) * | 2022-03-21 | 2023-09-29 | 苏州科锐迈德生物医药科技有限公司 | 一种脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
KR102560772B1 (ko) * | 2022-03-21 | 2023-07-28 | 주식회사 메디치바이오 | 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물 |
WO2023220734A2 (en) * | 2022-05-13 | 2023-11-16 | The Trustees Of The University Of Pennsylvania | Bisphosphonate lipids, lipid nanoparticle compositions comprising the same, and methods of use thereof for targeted delivery |
WO2023232747A1 (en) * | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2853689A (en) * | 1954-02-10 | 1958-09-23 | Jackson Anton | Printed circuit contact receptacle |
WO2010062322A2 (en) * | 2008-10-27 | 2010-06-03 | Massachusetts Institute Of Technology | Modulation of the immune response |
NO2355851T3 (pt) * | 2008-11-10 | 2018-09-01 | ||
RU2573409C2 (ru) * | 2009-11-04 | 2016-01-20 | Дзе Юниверсити Оф Бритиш Коламбиа | Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы |
AU2012353463B2 (en) * | 2011-12-12 | 2017-08-24 | Kyowa Hakko Kirin Co., Ltd. | Lipid nanoparticles containing combinations of cationic lipids |
PT3368507T (pt) * | 2015-10-28 | 2023-02-07 | Acuitas Therapeutics Inc | Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos |
JP2019533707A (ja) * | 2016-11-10 | 2019-11-21 | トランスレイト バイオ, インコーポレイテッド | Mrna担持脂質ナノ粒子を調製する改善されたプロセス |
WO2020051223A1 (en) * | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
BR112021014845A2 (pt) * | 2019-01-31 | 2021-11-03 | Modernatx Inc | Métodos de preparação de nanopartículas lipídicas |
-
2021
- 2021-10-13 CA CA3195123A patent/CA3195123A1/en active Pending
- 2021-10-13 WO PCT/US2021/054837 patent/WO2022081750A1/en active Application Filing
- 2021-10-13 BR BR112023006710A patent/BR112023006710A2/pt unknown
- 2021-10-13 JP JP2023523610A patent/JP2023546175A/ja active Pending
- 2021-10-13 US US17/500,491 patent/US20220235377A1/en active Pending
- 2021-10-13 IL IL301890A patent/IL301890A/en unknown
- 2021-10-13 EP EP21881026.5A patent/EP4229208A1/en active Pending
- 2021-10-13 TW TW110138031A patent/TW202229228A/zh unknown
- 2021-10-13 KR KR1020237016058A patent/KR20230118715A/ko unknown
- 2021-10-13 JP JP2023524079A patent/JP2023546908A/ja active Pending
- 2021-10-13 AU AU2021360494A patent/AU2021360494A1/en active Pending
- 2021-10-13 CA CA3195093A patent/CA3195093A1/en active Pending
- 2021-10-13 TW TW110137995A patent/TW202228725A/zh unknown
- 2021-10-13 WO PCT/US2021/054839 patent/WO2022081752A1/en active Application Filing
- 2021-10-13 US US17/500,486 patent/US20220218622A1/en active Pending
- 2021-10-13 MX MX2023004371A patent/MX2023004371A/es unknown
- 2021-10-13 AU AU2021362206A patent/AU2021362206A1/en active Pending
- 2021-10-13 EP EP21881024.0A patent/EP4228658A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220235377A1 (en) | 2022-07-28 |
IL301890A (en) | 2023-06-01 |
TW202229228A (zh) | 2022-08-01 |
US20220218622A1 (en) | 2022-07-14 |
AU2021362206A1 (en) | 2023-05-18 |
JP2023546175A (ja) | 2023-11-01 |
CA3195093A1 (en) | 2022-04-21 |
KR20230118715A (ko) | 2023-08-11 |
EP4228658A1 (en) | 2023-08-23 |
WO2022081752A1 (en) | 2022-04-21 |
CA3195123A1 (en) | 2022-04-21 |
AU2021360494A1 (en) | 2023-05-18 |
EP4229208A1 (en) | 2023-08-23 |
TW202228725A (zh) | 2022-08-01 |
WO2022081750A1 (en) | 2022-04-21 |
JP2023546908A (ja) | 2023-11-08 |
MX2023004371A (es) | 2023-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023006710A2 (pt) | Métodos de fabricação de nanopartícula lipídica e composições derivadas da mesma | |
Verbeke et al. | Innate immune mechanisms of mRNA vaccines | |
Han et al. | Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems | |
Abbas Momtazi et al. | Difluorinated curcumin: a promising curcumin analogue with improved anti-tumor activity and pharmacokinetic profile | |
MX2022000934A (es) | Composiciones estables de nanoparticulas lipidicas cargadas de arnm y procesos de fabricacion. | |
CA3173922A1 (en) | Rna constructs and uses thereof | |
Fröhlich et al. | Structure–activity relationships of siRNA carriers based on sequence-defined oligo (ethane amino) amides | |
JP2017523965A5 (pt) | ||
US20160324781A1 (en) | Novel lipids and compositions for intracellular delivery of biologically active compounds | |
CY1121122T1 (el) | Πολυαιθυλενογλυκολιωμενα λιποσωματα για απελευθερωση rna που κωδικοποιει ανοσογονο | |
Klein et al. | Precise redox-sensitive cleavage sites for improved bioactivity of siRNA lipopolyplexes | |
MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
US10081598B2 (en) | Cationic lipid | |
CA3113151A1 (en) | Rna particles comprising polysarcosine | |
Gaynanova et al. | Self-assembling drug formulations with tunable permeability and biodegradability | |
Tilstra et al. | Iterative design of ionizable lipids for intramuscular mRNA delivery | |
JP2017503502A5 (pt) | ||
US7741357B1 (en) | Heterocyclic and carbonate derivatives of NDGA and their use as new anti-HIV and anti-cancer agents | |
BR112022013837A2 (pt) | Nanopartículas lipídicas | |
BR112014017756A8 (pt) | Sistema de administração transmucosa para um medicamento | |
TW201532614A (zh) | 陽離子性脂質 | |
EA202191315A1 (ru) | Катионные липиды, содержащие кремний | |
WO2022152141A3 (en) | Polymer conjugated lipid compounds and lipid nanoparticle compositions | |
Qian et al. | Therapeutic delivery of nitric oxide utilizing saccharide-based materials | |
Niazi | RNA therapeutics: A healthcare paradigm shift |